Maravai LifeSciences

(NASDAQ) MRVI

Current Price$7.10

Market Cap$1.04B

Since IPO (2020)-76%

5 Year-81%

1 Year+172%

1 Month+42%

Maravai LifeSciences last closing stock price
Metric	Price	Date
Last close	USD 7.04	2026-07-15

Maravai LifeSciences stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+22.22%	USD 5.76	2026-07-08
1 month	+41.94%	USD 4.96	2026-06-15
3 month	+106.45%	USD 3.41	2026-04-16
Year to date	+116.62%	USD 3.25	2025-12-31
1 year	+171.81%	USD 2.59	2025-07-15
3 year	-44.96%	USD 12.79	2023-07-14
5 year	-80.87%	USD 36.80	2021-07-16
Since inception	-76.42%	USD 29.85	2020-11-20

Maravai LifeSciences Financials at a Glance

Market Cap

$1.04B

Revenue (TTM)

$204.73M

Net Income (TTM)

-$104.56M

EPS (TTM)

-$0.72

P/E Ratio

-9.74

Dividend

$0.00

Beta (Volatility)

1.12 (Average)

Dividend

$0.00

Beta (Volatility)

1.12 (Average)

Price

$7.10

Volume

5,236,478.208

Open

$7.04

Price

$7.10

Volume

5,236,478.208

Open

$7.04

Previous Close

$7.09

Daily Range

$6.66 - $7.12

52-Week Range

$1.99 - $7.12

Estimated Earnings Date

Aug 10, 2026

Dividend

$0.00

Beta (Volatility)

1.12 (Average)

Price

$7.10

Volume

5,236,478.208

Open

$7.04

Previous Close

$7.09

Daily Range

$6.66 - $7.12

52-Week Range

$1.99 - $7.12

Estimated Earnings Date

Aug 10, 2026

MRVI News

Business people shaking hands in conference room.

MRVI: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Maravai LifeSciences

Maravai helps scientists make new vaccines and medicines. They make building blocks for gene and cell therapies. Their tools help catch impurities during drug manufacturing.

The Building Blocks of Biotech

TriLink segment: Provides complex nucleic acids like mRNA and CleanCap capping technology; accounts for 64% of revenue.
Cygnus segment: Focuses on biologics safety testing and analytical impurity detection; represents 36% of revenue.
CleanCap technology: Proprietary chemical reagents used to stabilize and improve the performance of mRNA-based medicines.
Safety testing kits: Analytical tools that detect host cell proteins and other leftover materials during drug production.

Recent Moves and Big Changes

Announced the 2025 Corporate Realignment Plan in August 2025 to reduce the workforce and lower costs.
Appointed a new Chief Executive Officer and a new Chief Financial Officer in June 2025.
Renamed the reportable business segments to TriLink and Cygnus during fiscal year 2025.
Incorporated AI technology from Officinae Bio to help customers design and optimize better mRNA sequences.

What Sets Maravai Apart

Maravai operates specialized manufacturing facilities across California, North Carolina, Virginia, and Florida to support global drug production. The company holds exclusive patents for CleanCap technology, which improves the efficiency of messenger RNA manufacturing for its pharmaceutical clients.

The Latest Financial Scorecard

Revenue was $49.9 million in Q4 2025, down 11.6% year-over-year.
Operating loss narrowed to $6.7 million in Q4 2025, an 82.3% improvement from Q4 2024.
Gross profit reached $12.2 million in Q4 2025, down 35.4% from the previous year.
Free cash flow worsened to -$24.9 million in Q4 2025, down 21.5% compared to Q4 2024.

The Final Word

Maravai is transforming from a pandemic-focused supplier into a specialized partner for diverse gene therapy developers. The company is currently restructuring its operations to focus on sustainable growth within the biologics safety market.

AI Generated • May 5, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

435

CEO

Bernd Brust

Website

www.maravai.com

Headquarters

San Diego, CA 92121, US

MRVI Financials

Key Financial Metrics (TTM)

Gross Margin

29.00%

Operating Margin

21.93%

Net Income Margin

-51.07%

Return on Equity

-44.72%

Return on Capital

-2.72%

Return on Assets

-14.66%

Earnings Yield

-10.27%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.04B

Shares Outstanding

147.51M

Volume

5.24M

Avg. Volume

2.94M

Financials (TTM)

Gross Profit

$59.37M

Operating Income

$44.90M

EBITDA

-$103.91M

Operating Cash Flow

-$39.52M

Capital Expenditure

-$12.35M

Free Cash Flow

-$51.87M

Cash & ST Invst.

$165.92M

Total Debt

$270.88M

Maravai LifeSciences Performance Analysis

Maravai LifeSciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 883,001,000	10.5%
2023	2023-12-31	USD 288,945,000	-67.3%
2024	2024-12-31	USD 259,185,000	-10.3%
2025	2025-12-31	USD 185,743,000	-28.3%

Maravai LifeSciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	1.2%
Q3	2025-09-30	-12.2%
Q4	2025-12-31	19.8%
Q1	2026-03-31	32.0%

Maravai LifeSciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD 1.67	7.0%
2023	2023-12-31	USD -0.90	N/A
2024	2024-12-31	USD -1.05	16.4%
2025	2025-12-31	USD -0.91	-13.7%

Maravai LifeSciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-28.6%
Q3	2025-09-30	33.3%
Q4	2025-12-31	-38.9%
Q1	2026-03-31	89.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$65.84M

+40.5%

Gross Profit

$33.70M

+336.3%

Gross Margin

51.19%

N/A

Market Cap

$1.04B

N/A

Market Cap/Employee

$2.50M

N/A

Employees

416

N/A

Net Income

-$3.73M

+87.5%

EBITDA

$12.20M

+139.3%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$165.92M

-41.8%

Total Debt

$270.88M

-17.1%

Accounts Receivable

$33.42M

+17.3%

Inventory

$40.46M

-18.7%

Long Term Debt

$265.44M

-17.1%

Short Term Debt

$5.44M

-13.3%

Return on Assets

-14.66%

N/A

Return on Invested Capital

6.70%

N/A

Free Cash Flow

$4.23M

+128.9%

Operating Cash Flow

$8.67M

+192.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

KURAKura Oncology, Inc.

KURAKura Oncology, Inc.$10.89-3.88%

REPLReplimune Group, Inc.

REPLReplimune Group, Inc.$9.52-1.65%

SEPNSepterna Inc

SEPNSepterna Inc$31.56-7.37%

PRMEPrime Medicine, Inc.

PRMEPrime Medicine, Inc.$3.22-7.74%

BCAXBicara Therapeutics Inc. Common Stock

BCAXBicara Therapeutics Inc. Common Stock$27.60-1.83%

DNAGinkgo Bioworks Holdings, Inc.

DNAGinkgo Bioworks Holdings, Inc.$8.29-7.89%

VIRVir Biotechnology, Inc.

VIRVir Biotechnology, Inc.$9.40-2.19%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$15.60-0.00%

ATAIAtaiBeckley

ATAIAtaiBeckley$7.15+0.33%

ONDSOndas

ONDSOndas$6.65-0.06%

SOFISoFi Technologies

SOFISoFi Technologies$17.32-0.03%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$70.74-0.05%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$40.89+0.05%

LCIDLucid Group

LCIDLucid Group$6.46+0.09%

Questions About MRVI

What is the current price of Maravai LifeSciences?

Maravai LifeSciences is trading at $7.09 per share.

What is the 52-week range for Maravai LifeSciences?

Over the past 52 weeks, Maravai LifeSciences has traded between $1.99 and $7.12.

How much debt does Maravai LifeSciences have?

As of the most recent reporting period, Maravai LifeSciences reported total debt of $270.88M.

How much cash does Maravai LifeSciences have on hand?

Maravai LifeSciences reported $165.92M in cash and cash equivalents in its most recent financial results.

What is Maravai LifeSciences’s dividend yield?

Maravai LifeSciences does not currently have a dividend yield.

Maravai LifeSciences

Maravai LifeSciences Financials at a Glance

MRVI News

2 Healthcare Companies That Could Be Acquired Within 5 Years

2 Biotech Stocks You Can Buy and Hold for the Next Decade

This Fallen Growth Stock Is Still a Wall Street Favorite: Here's Why

3 of the Best Bear Market Buys for August

Forget Robinhood and Buy These 2 Growth Stocks Instead

1 Biotech Stock Investors Should Know About

Why Maravai LifeSciences Tumbled Nearly 12% Today

MRVI: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Maravai LifeSciences

The Building Blocks of Biotech

Recent Moves and Big Changes

What Sets Maravai Apart

The Latest Financial Scorecard

The Final Word

MRVI Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Maravai LifeSciences Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About MRVI

What is the current price of Maravai LifeSciences?

What is the 52-week range for Maravai LifeSciences?

How much debt does Maravai LifeSciences have?

How much cash does Maravai LifeSciences have on hand?

What is Maravai LifeSciences’s dividend yield?

Premium Investing Services